Peripheral plasma levels of progesterone in goats treated with fluorogestone acetate and prostaglandin F2α during the estrous cycle

Intravaginal pessaries impregnated with 20 mg fluorogestone acetate (FGA) were inserted into fifteen does at various intervals after the end of estrus. After resumption of cyclical activity following withdrawal of the intravaginal pessaries, the does were divided into six groups and treated with prostaglandin F2_α. Each doe received 15 mg Prostaglandin F2_α administered intramusuclarly 2, 4, 6, 12, 14 or 16 days after the end of estrus. The animals were bred naturally on the first estrus following prostaglandin treatment. Jugular blood samples were collected from each doe throughout the experimental period. The plasma samples were assayed for progesterone. Intravaginal fluorogestone acetate treatment in does had no effect on the function of the corpus luteum, however, overt estrus was postponed during treatment and for a few days after removal of the pessaries. Prostaglandin injection into does, 4, 6, 12, 14 or 16 days after the end of estrus induced luteolysis and subsequent ovulatory estrus within 2 to 3 days. Fertility at PGF2_α induced estrus in these does was 77%. Prostaglandin treatment two days after the end of estrus had no effect on the corpus luteum function. It is concluded that prostaglandin is luteolytic when administered into does anytime beyond four days after the end of estrus.     

A study of prostaglandin F2α as the luteolysin in swine: I. Effect of prostaglandin F2α in hysterectomized gilts

Experiments were conducted to determine if prostaglandin F_2α (PGF_2α) is luteolytic in swine. In Experiment 1, four bilaterally hysterectomized gilts were injected with PGF_2α at 0800 (10mg) and 2000 hours (10mg) and four gilts received .9% saline at the same times on day 17 after onset of estrus. Treatments were reversed in the two groups of gilts 21 days later. All eight PGF_2α treated gilts exhibited estrus an average of 88.0 ± 13.5 hours after treatment and average duration of estrus was 66.0 ± 16.4 hours. Saline treated controls did not exhibit estrus. Two additional gilts were hysterectomized bilaterally and the saphenous artery catheterized on day 7 after onset of estrus. PGF_2α injected on day 17 resulted in a precipitous decline in plasma progestin concentration and onset of estrus by 110 and 90 hours in gilts 1 and 2, respectively. Another bilaterally hysterectomized gilt, with CL marked with India ink, received PGF_2α on day 17. Estrus occurred 92 hours later and, on day 4, regression of marked CL to corpora albicantia and presence of newly formed CL was confirmed at laparotomy.In Experiment 2, 12 bilaterally hysterectomized gilts were treated with PGF_2α at 0800 (10mg) and 2000 hours (10mg) on either day 8, 11, 14 or 17 after onset of estrus. None of the gilts treated on days 8 and 11 exhibited estrus. Two of three gilts treated on day 14 and all three gilts treated on day 17 exhibited estrus at an average of 116.0 ± 9.8 hours post-treatment. Average duration of estrus was 49.6 ± 8.8 hours.     

Prostaglandin induced early abortions in the bovine. Clinical outcome and endogenous release of prostaglandin F2α and progesterone

Peripheral blood plasma levels of progesterone and the main blood plasma metabolite of prostaglandin F_2α (15-keto-13, 14-dihydro-PGF_2α) were analysed in 12 heifers in which abortions were induced with a prostaglandin analogue (cloprostenol) at pregnancy stages from 39–146 days. All animals except one (treated on day 75 of pregnancy) aborted within 4 days following treatment.The peripheral plasma levels of progesterone decreased rapidly following the injection of cloprostenol. All heifers had shortlasting peaks of the prostaglandin metabolite in connection with luteal regression. In animals pregnant for less than 80 days this release ceased at the time of delivery of the fetuses, which were expelled within unruptured fetal membranes. Standing estrus was observed in connection with the expulsion of the fetuses. Two of the animals were mated at this estrus and became pregnant. In contrast, animals pregnant for more than 100 days released massive amounts of prostaglandin F_2α during a 2–5-days period post partum and had retained fetal membranes. No heat was observed in connection with these abortions. The animal that failed to abort showed no change in the prostaglandin metabolite levels.     

The influence of ovarian status on response to estrus synchronization treatment in dairy goats during the breeding season

The influence of ovarian status (presence of a corpora lutea and follicles) on the times of the onset of estrus, LH peak and ovulation rate at a synchronized estrus was evaluated in 73 Alpine and Saanen cyclic goats. Does were treated for 11 d with 3 mg norgestomet implants or 45mg fluorogestone acetate (FGA) sponges. They also received 400 IU of PMSG and 50 μg of a PGF_2α analog on Day 9 of progestagen priming. Follicles (1 to 7 mm) and corpora lutea (CL) were counted by laparoscopy on Days 0 and 9 of progestagen treatment and 5 or 6 d after the synchronized estrus. Estrus was detected every 4 h from 16 to 60 h after the end of progestagen treatment using a vasectomized buck. The LH concentration was determined by radioimmunoassay (RIA) in blood samples collected every 4 h for 24 h beginning at the time of the onset of estrus. The number of follicles on Days 0 and 9 of progestagen treatment was not related to the time of the onset of estrus and occurrence of the LH peak or to ovulation rate. The number of CL on Day 9 influenced the time of occurrence of the LH peak but not the time of the onset of estrus. Thus, in does with 2 or 3 CL on Day 9, the LH peak occurred at 46.9 h after the end of progestagen treatment, and in does with 1 or 0 CL at 42.2 and 42.5 h, respectively, after treatment, suggesting that the number of CL at luteolysis is a factor in the variability of response after the synchronization of estrus.     

Use of short-term progestin treatment to resynchronize the second estrus following synchronized breeding in beef heifers

Two trials were conducted to evaluate the efficacy of short-term progestin administration to resynchronize the second estrus after artificial insemination in yearling beef heifers. In Trial 1 crossbred yearling heifers (n = 208) were synchronized with Syncro-Mate-B (SMB) and artificially inseminated (AI) between 48 and 54 h following implant removal. Implant removal is defined as Day 1. Following AI, the heifers were randomly assigned to 1 of 2 experimental groups. Group 1 heifers were fed melengestrol acetate (MGA) daily from Day 17 to 21 at a rate of 0.5 mg/head, while Group 2 control received no exogenous progestin during this period. Synchrony of estrus was defined as the 3-d period in which the highest number of heifers expressed behavioral estrus in each group. There was no difference (P < 0.05) in the pregnancy rate during the second estrus due to MGA supplementation. More MGA-treated heifers (P < 0.01) expressed estrus in a 3-d period than the controls. In Trial 2, yearling heifers (n = 108) were synchronized with 2 injections of PGF(2alpha) (second PGF(2alpha) injection is designated as Day 1) administered 14 d apart with AI 12 h after the onset of behavioral estrus. The heifers were then randomly assigned to 1 of the following 3 treatment groups after initial AI: 1) MGA fed at 0.5 mg/head daily from Days 17 to 21; 2) norgestomet administered in 6.0-mg implants from Days 17 to 21; 3) untreated control heifers. Blood samples were collected on Day 21 and analyzed for progesterone (P(4)). Elevated P(4) (> 1 ng/ml) on Day 21 indicated pregnancy to the first insemination. Synchrony among the 3 groups of heifers was similar (P > 0.10); however, the second estrus was less (P < 0.05) variable in the MGA and norgestomet treated heifers. During the resynchronized second estrus, conception rates were not affected by progestin treatment (MGA 40%, norgestomet 64%, and control 62%; P > 0.10). However, a proportion of heifers treated MGA 10% 4 36 and norgestomet 3% 1 36 expressed behavioral estrus during second estrus even though they were diagnosed as pregnant from first service by elevated P(4) levels on Day 21. We conclude that short-term use of progestin from Days 17 to 21 following AI causes closer synchrony of estrus; however, inseminating pregnant heifers that exhibit behavioral estrus may cause abortion.     

Corpus luteum function in the ewe: Effect of PGF2α and prostaglandin synthetase inhibitors

A series of experiments were conducted to evaluate the effects of mode and frequency of administration and estrous cycle stage on the response of the cycling ewe to PGF_2α. The effects of dexamethasone, arachadonic acid and prostaglandin synthetase inhibitors on estrous cycle length and plasma progesterone levels were also determined.Intramuscular administration of 5 or 10 mg of PGF_2α, on days 8 and 9 after estrus (5 ewes/group), significantly (p<.01) shortened the mean length of the estrous cycle and the interval from the end of treatment to estrus. Mean plasma progesterone levels, 24 hours after initial injection, were significantly (p<.01) lowered. When administered on day 8 only, these doses were considerably less effective in shortening estrous cycle length or lowering plasma progesterone levels. Intravaginal administration of PGF_2α, by polyurethane tampon, was also largely ineffective.Treatment of ewes with 10 mg of PGF_2α i.m., on days 3 and 4 of the estrous cycle, resulted in a return to estrus in 2 days in 25% of the treated animals. Plasma progesterone levels of PGF_2α-treated ewes were significantly lower than controls on the second, third and fourth days after the start of dosing. It would appear that PGF_2α exerts a retarding effect on developing CL functionality.The prostaglandin synthetase inhibitors, aspirin, flufenamic acid and 1-p-chlorobenzylidene-2-methyl-5-methoxy-3-indenylacetic acid, were administered orally or parenterally for 16 days beginning on day 8 of the estrous cycle. These compounds failed to prolong estrous cycle length. Parenteral administration of dexamethasone did not result in PGF_2α release in the cycling ewe, at least not in quantities sufficient to induce luteolysis. The prostaglandin precursor, arachadonic acid, also was not luteolytic when given parenterally to cycling ewes.     

Estrus synchronization and controlled breeding in goats using prostaglandin F(2)alpha

Estrus synchronization in the goat employing the double injection regimen of 7.5 mg of prostaglandin F(2)alpha (Lutalyse) at each injection, resulted in 64% and 84% synchronization at first and second injections, respectively. Breeding at estrus induced by the second injection resulted in 90% conception. Kidding at the end of the gestation period was spread over a 17-day period. The first and the last does had 141 and 158 days of gestation, respectively. The findings of this study indicate that two injections of prostaglandin F(2)alpha 10 days apart is superior to a single injection for estrus synchronization in the goat. Breeding following the second injection resulted in high conception rate. Due to individual differences in gestational lengths, estrus synchronization with prostaglandin F(2)alpha cannot be depended upon for synchrony of kidding.     

Efficacy of a prostaglandin analogue in reproduction in the cycling mare.

A prostaglandin F analogue caused luteolysis in normal cycling non-lactating mares, and lactating mares (treated after the foal estrus). Effective doses ranged from 1.0 to 4.0mg given as a single subcutaneous injection 8–10 days after ovulation. A dose of 0.5mg was ineffective, hence the dose-response relationship was steep, indicative of a quantal type of response. Mares usually returned to estrus within 2–4 days and ovulated by 7 days after treatment. Mares bred naturally or by artificial insemination at the induced estrus and ovulation were fertile. The compound was without side-effects, and hence should be of value in manipulating the estrous cycle of the mare.     

Progestin treatment for infertility in bitches with short interestrus interval

The purpose of this study was to investigate if the suppression of estrus by the administration of a synthetic progestin, megestrol acetate or clormadinone acetate, could be an effective treatment to infertility in bitches with shortened interestrus periods and previous infertility. Ten bitches of different breeds and ages, with history of infertility and presenting repeated interestrus intervals of less than 4 months, were treated daily either with megestrol acetate (2 mg/kg, n = 8) or clormadinone acetate (0.5 mg/kg, n = 2) orally for 8 days. The treatments were begun within a maximum of 3 days after the onset of clinical signs of proestrus. Estrus was prevented in all animals and appearance of the following proestrus cycle was observed within 2.7 +/- 0.6 months (mean +/- S.D.) after the beginning of the treatment. When mated during the first post-treatment estrous cycle, bitches became pregnant and whelped normal healthy offspring. No negative side effects were clinically detected over the study period. Our results show that, in bitches with shortened interestrus intervals and previous infertility, suppression of one estrus with synthetic progestins administered at recommended doses, allows fertile breedings on the subsequent cycle, producing litter sizes within the normal range.     

A two injection schedule with prostaglandin F2alpha for the regulation of the ovulatory cycle of cattle

Thirty randomly cycling Holstein heifers were given two injections of prostaglandin F_2α 10 days apart, to determine whether this treatment would cause most of the animals to show estrus shortly after the second injection. Twenty-five of the 30 heifers (83%) were in estrus and inseminated 2 to 4 days following the second injection and 10 of the 25 (40%) were pregnant at 60 days post insemination. Thirteen of 15 control heifers (87%) were detected in estrus over a 3 week period and seven of the 13 (54%) were pregnant at 60 days. Chi square analysis indicated that the proportion of animals showing estrus and subsequent pregnancy in the treated and in the control groups were not significantly different. The two injection system may have commercial application for the regulation of the ovulatory cycle of cattle.     

Comparison of controlled internal drug release device and melengesterol acetate as progestin sources in an estrous synchronization protocol for beef heifers

The objectives of this experiment were to compare estrous synchronization responses and AI pregnancy rates of beef heifers using protocols that included either CIDR or MGA as the progestin source. The hypotheses tested were that: (1) estrous synchronization responses after (a) progestin removal, and (b) PGF(2alpha); and, (2) AI pregnancy rates, do not differ between heifers synchronized with either progestin source. At the start of the experiment (Day 0) in both years, heifers were assigned randomly to receive, MGA supplement for 14 days (MGA-treated; n=79) or CIDR for 14 days (CIDR-treated; n=77). On Day 14 progestin was removed and heifers were observed for estrus up to and after PGF(2alpha) on Days 31 and 33 for CIDR-treated and MGA-treated heifers, respectively. Heifers that exhibited estrus within 60h after PGF(2alpha) were inseminated by AI 12h later; the remaining heifers were inseminated at 72h after PGF(2alpha) and given GnRH (100mug). More (P<0.05) CIDR-treated heifers exhibited estrus within 120h after progestin removal than MGA-treated heifers. Intervals to estrus after progestin removal were shorter (P<0.05) for CIDR-treated heifers than MGA-treated heifers. More (P<0.05) CIDR-treated heifers exhibited estrus and were inseminated within 60h after PGF(2alpha) than MGA-treated heifers. Pregnancy rates did not differ (P>0.10) between MGA-treated (66%) and CIDR-treated (62%) heifers. In conclusion, the use of CIDR as a progestin source in a 14-day progestin, PGF(2alpha), and timed AI and GnRH estrous synchronization protocol was as effective as the use of MGA to synchronize estrus and generate AI pregnancies in beef heifers.     

Steroid priming shortens prostaglandin-based estrus synchronization program from 14 to 7 days in cattle

Single injection of estrogen and progesterone before prostaglandin (steroid priming) was used to shorten the prostaglandin-based estrus synchronization program. Sixty-five cyclic Sistani cattle, with parity ranging from 1 to 4 and postpartum period of >80 days were selected at unknown stages of the estrous cycle and assigned to 2 groups according to their age, weight and parity. Females in the control group (n=33; 58.4 +/- 4.3 months; 277 +/- 8 kg LW) received two consecutive injections of prostaglandin F2alpha analogue (500 microg; Cloprostenol, PG) 14 days apart (Day 0 = First PG injection). On Day 7, treated females (n=32; 60 +/- 4.8 months; 292 +/- 9 kg LW) were given an intramuscular injection of 100 mg progesterone and 2 mg estradiol benzoate followed by prostaglandin 7 days later, concurrent with the second PG injection of the control group. Estrus detection was carried out every 6 hours for 7 days, commencing from 24 hours after the last PG injection. Females that allowed to be mounted were identified (standing estrus) and inseminated with frozen semen 12 hours later. Pregnancy was diagnosed on Day 50 after AI through palpation per rectum. Data were analyzed using Chi-squared and t-test. The tightness of estrus synchrony (%), the interval from the end of treatment to estrus (h) and conception rates (%) were similar (P > 0.05) between control (69.6%, 77.7 +/- 5.96 h and 56.5%) and treatment (68.2%, 82.6 +/- 7.64 h and 54.5%) groups. In conclusion, steroid priming is an efficient way to shorten the prostaglandin-based estrus synchronization program from 14 to 7 days without compromising estrous response and fertility.     

Effect of gonadotropin-releasing hormone and prostaglandin F2α on reproduction in postpartum dairy cows

Thirty dairy cows serving as the treated group (Group A) were injected intramuscularly with 100 mcg gonadotropin-releasing hormone (GnRH) at 10 to 16 days postpartum followed by 25 mg prostaglandin F₂α (PGF₂α) 14 days later. Twenty-nine herdmate dairy cows (Group B) serving as controls were treated in a similar manner using saline injections rather than GnRH or PGF₂α treatments. Only cows without obvious uterine infection were assigned to the experimental groups, and any uterine pathology that developed during the treatment interval was treated accordingly following the experimental period. Internal genitalia were evaluated via rectal palpation prior to each injection. Blood samples were collected for progesterone analysis before each injection and at 30 hours following the PGF₂α or the second saline injection. Experimental animals were artificially inseminated at the first detected postpartum estrus starting 35 to 40 days following calving. Results indicated evidence of enhanced cyclicity when Group A cows were compared with those in Group B. However, there were no significant differences between the two groups for interval to first observed estrus, interval to first serive, first serive pregnancy rate, services per pregnancy and days open. Furthermore, no difference in the incidence of follicular or luteal cysts, incidence of repeat breeders or number of reproductive culls was observed. From observations in this study, the GnRH and PGF₂α treatment scheudule might not be economically beneficial in lactating dairy cows as long as reproductive tract abnormalities are promptly diagnosed and subsequently treated by the attending practitioner.     

Control of estrus and ovulation in dairy cows

The efficiency of a synthetic prostaglandin analog (ICI 80996) for the control of the estrus cycle in dairy cows has been tested with and without simultaneous use of progestagen implants (SC 21009, Searle). Synchronization of estrus is closer after combined progestagen-prostaglandin treatments than after prostaglandins alone (78.7 % in estrus in 48h vs 60.2 % ; P<0.001).The percentage of cows not observed in estrus during the first 96h after the end of treatment was also lower after combined treatments (20.7 % vs 31.8 % ; P<0.05). The best estrus synchronization was obtained by injecting prostaglandin analog two days before implant removal (86 % in estrus in 48h and 14.0 % not observed in estrus within 96h).Fertility was studied in a field trial after one or two inseminations at a predetermined time for each treatment. A higher pregnancy rate was obtained with two inseminations after combined progestagen-prostaglandin treatment (49.1 %). This pregnancy rate differed significantly (P<0.05) from those obtained with one A.I. after the same treatment or two A.I. after the prostaglandin treatment but did not differ from the pregnancy rate obtained with one A.I. 80h after the second prostaglandin injection. The most important problem in dairy cows is the fall in pregnancy rate between 21 days and 6 months (19.7 to 35.1 % depending on treatment ; P<0.05).     

Effects of GnRH on superovulated cattle

Gonadotropin releasing hormone (GnRH) was given to 109 cows and heifers during the course of 224 superovulations. Follicle stimulating hormone (FSH) was administered twice daily (5 or 6 mg) for 3.5 to 4 days beginning on any of Days 9 to 14 of the estrous cycle; prostaglandin (45 mg PGF(2)alpha or 750 ug cloprostenol) was given in a split dose on the fourth day. Donor cows and heifers were placed into four groups according to previous superovulation treatments, which consisted of one to three treatments or of no previous treatment. Every other cow or heifer within each of the four subgroups was treated with GnRH (200 mug i.m.) at standing estrus. Only donors that exhibited estrus within 32 to 72 h after the first prostaglandin treatment were used in the study. Animals were inseminated artificially 12 and 24 h after standing estrus was first observed. No differences were noted in the number of ovulations, total ova or transferable embryos recovered from the GnRH or control groups; however, two interactions were detected. Cows given GnRH had fewer palpable corpora lutea than control cows (P < 0.05), but this difference was not seen in heifers. The second interaction was that GnRH seemed to depress ovulation rate in donors not previously superovulated, but this effect was not observed with subsequent superovulations. Cows yielded more total ova than heifers (P < 0.01). There was no difference in return to estrus between GnRH and control groups after a second prostaglandin treatment at the time of embryo recovery. Most donors within each group resumed cycling between 5 and 12 d after embryo recovery.     

Progesterone and estradiol in biodegradable microspheres for control of estrus and ovulation in mares

Progesterone and estradiol 17-beta in poly (DL-lactide) microspheres were used to control estrus and ovulation in mares after luteolysis was induced by prostaglandin F(2)infinity. Mares were given a single intramuscular injection of biodegradable poly (DL-lactide) microspheres, 1 day following prostaglandin treatment, containing no hormones (control), 0.625 g progesterone and 50 mg estradiol (low dose), 1.25 g progesterone and 100 mg estradiol (medium dose), or 1.875 g progesterone and 150 mg estradiol (high dose; n=15 mares per group). Mares treated with the low dose had significantly longer intervals (P<0.05) to estrus and ovulation than the control mares; however, low dose mares had shorter intervals (P<0.05) to estrus than high dose mares and shorter intervals to ovulation than medium and high dose mares. Regression analysis indicated that the medium dose was sufficient for maximizing interval to ovulation while the high dose maximized interval to estrus. All groups of mares exhibited similar (P>0.05) post-treatment estrus lengths. A clinical response scoring system based on synchrony of both estrus and ovulation within a treatment group was also used to measure the effectiveness of treatments on control of estrus and ovulation. Clinical response scores did not differ (P>0.05) among treatment groups. Mares were randomly assigned for insemination at the beginning of the first post-treatment estrus. Rates for embryo recovery performed by uterine lavage 7 days post-ovulation did not differ (P>0.05) among groups. Concentrations of serum progesterone increased in mares receiving progesterone and estradiol microspheres. At 10 to 14 days post-injection of microspheres, progesterone concentrations were higher (P<0.05) and remained above 1 ng/ml in the mares receiving the high dose. Progesterone concentrations were also higher (P<0.05) on Days -3 to -1 (Day 0 = day of post-treatment ovulation) in mares receiving the high dose when compared to control mares. Gonadotropin concentrations were suppressed (P<0.05) in the medium and high dose groups.     

A new progestin (Sa 45.249) for cycle control in pigs communication I: Hormonal activities and dosage

Sa 45.249 was applied for 12 days to groups of ten gilts each. A daily dose of 3, 6, 12 or 24 mg inhibited cyclic functions effectively; estrus was observed 4.5 ± 0.8, 4.8 ± 0.8, 5.2 ± 0.9 and 6.1 ± 0.6 days after cessation of treatment, respectively. All animals were slaughtered 8 days after induced estrus. Only animals treated with 3 mg showed a high incidence of ovarian cysts simultaneously with the occurrence of corpora lutea. In animals treated with higher dosages, only one (6 mg) had 4 cystic follicles, but simultaneously 12 corpora lutea. In another study, the effectiveness of Sa 45.249, applied at different doses, for differing time periods, and starting at different days of the cycle, was investigated. Doses ranged from 3 to 9 mg/day, duration of treatment from 8 to 16 days and treatments commenced on days 2, 5, 10, 15 or 19 of the cycle. An increase in the daily doses of 1 mg resulted in a delay of estrus of less than 0.1 day. Of 99 gilts, 93 showed an estrus 6.5 ± 1.7 days after cessation of treatment. None of the variables studied had a significant effect on the occurrence of estrus or the interval between treatment and the onset of heat.     

Jugular levels of 13,14-dihydro-15-keto-prostaglandin F and progesterone around luteolysis and early pregnancy in the ewe

Six non-pregnant ewes at day 12 of the estrous cycle each had a day-12 embryo transferred into the uterine horn ipsilateral to the corpus luteum, and 4 non-pregnant ewes at day 13 each had a day-13 embryo similarly transferred. Four control ewes, 2 at day 12 and 2 at day 13 received sheep serum into the uterine horn ipsilateral to the corpus luteum. Jugular blood samples were taken at 2-hourly intervals for 3 days post-surgery, then twice-daily for a further 4 days, and the plasma radioimmunoassayed for progesterone and 13,14-dihydro-15-keto-prostaglandin F. All control ewes exhibited estrus within the expected time range and pulsatile peaks of 13,14-dihydro-15-keto-prostaglandin F occurred coincident with declining progesterone levels. With one exception, the recipient ewes had prolonged cycles and those ewes found pregnant at necropsy, 30 days after transfer, showed no progesterone decline and no pulsatile peaks of prostaglandin during days 12 to 16 after estrus. These observations suggest that the presence of the embryo at a critical stage after mating suppresses the release of uterine prostaglandin F_2α.     

Fixed-time deep uterine insemination in PGF2α-synchronized goats

The aim of this investigation was to optimize fixed-time insemination in goats by clustering ovulations in prostaglandin F_2α-synchronized goats either with gonadotropin releasing hormone (GnRH) or human chorionic gonadotropin (hCG). The underlying intention was to reduce the incidence of short cycles by providing a more sustained stimulation of the corpus luteum by substituting the commonly used GnRH with longer-acting hCG. It was conjectured that this might render the corpus luteum less prone to premature regression. Sixty pluriparous does were administered 5 mg of the prostaglandin F_2α preparation dinoprost (Dinolytic; Pharmacia and Upjohn, Erlangen, Germany) during the luteal phase of the estrous cycle. Twenty of these does were administered 0.004 mg of the GnRH analog buserelin (Receptal; Intervet, Unterschleissheim, Germany) 48 hours later; another 20 does received 500 IU hCG (Chorulon; Intervet, Unterschleissheim, Germany) instead. Sixteen hours later the does were inseminated with frozen-thawed semen. The remaining 20 does served as controls and were inseminated 16-18 h after the onset of detected estrus. All 60 treated goats displayed estrous symptoms, the time of onset being similar for all groups (42.6, 37.6, and 40.5 hours after treatment for GnRH-treated, hCG-treated, and control does, respectively). The duration of estrus in the GnRH-treated group was 10 h less than in the other groups (45.1 vs. 56.4 and 54.4 h, P < 0.05). The number of ovulations (assessed by ultrasound monitoring) did not differ among groups (2.4, 2.1, and 2.5, P > 0.05). Monitoring of serum progesterone revealed that the incidence of corpus luteum insufficiency was significantly higher in GnRH- and hCG-treated does than in the control group (40% and 35% vs. 5%, P < 0.05). The pregnancy rate was 50% in the GnRH and 35% in the hCG group as compared with 60% in the controls. Corresponding kidding rates were 40%, 35%, and 60% (P > 0.05). When disregarding does with corpus luteum insufficiency, pregnancy rates would have been 83%, 54%, and 63%, and kidding rates 67%, 54%, and 63%, respectively. The average number of kids born was 1.88, 1.71, and 1.83, respectively (P > 0.05). It may be concluded that fixed time insemination of cycling does treated with prostaglandin F_2α during the luteal phase, followed by ovulation induction with GnRH or hCG, would be an effective management tool if it were possible to control the high incidence of corpus luteum insufficiency. The attempt to achieve this by substituting GnRH with hCG, was not met with success. Until a solution for the problem has been found, it is advisable to inseminate prostaglandin-synchronized does 16-18 hours after the onset of detected estrus.     

Fixed-time deep uterine insemination in PGF2α-synchronized goats

The aim of this investigation was to optimize fixed-time insemination in goats by clustering ovulations in prostaglandin F_2α-synchronized goats either with gonadotropin releasing hormone (GnRH) or human chorionic gonadotropin (hCG). The underlying intention was to reduce the incidence of short cycles by providing a more sustained stimulation of the corpus luteum by substituting the commonly used GnRH with longer-acting hCG. It was conjectured that this might render the corpus luteum less prone to premature regression. Sixty pluriparous does were administered 5 mg of the prostaglandin F_2α preparation dinoprost (Dinolytic; Pharmacia and Upjohn, Erlangen, Germany) during the luteal phase of the estrous cycle. Twenty of these does were administered 0.004 mg of the GnRH analog buserelin (Receptal; Intervet, Unterschleissheim, Germany) 48 hours later; another 20 does received 500 IU hCG (Chorulon; Intervet, Unterschleissheim, Germany) instead. Sixteen hours later the does were inseminated with frozen-thawed semen. The remaining 20 does served as controls and were inseminated 16–18 h after the onset of detected estrus. All 60 treated goats displayed estrous symptoms, the time of onset being similar for all groups (42.6, 37.6, and 40.5 hours after treatment for GnRH-treated, hCG-treated, and control does, respectively). The duration of estrus in the GnRH-treated group was 10 h less than in the other groups (45.1 vs. 56.4 and 54.4 h, P < 0.05). The number of ovulations (assessed by ultrasound monitoring) did not differ among groups (2.4, 2.1, and 2.5, P > 0.05). Monitoring of serum progesterone revealed that the incidence of corpus luteum insufficiency was significantly higher in GnRH- and hCG-treated does than in the control group (40% and 35% vs. 5%, P < 0.05). The pregnancy rate was 50% in the GnRH and 35% in the hCG group as compared with 60% in the controls. Corresponding kidding rates were 40%, 35%, and 60% (P > 0.05). When disregarding does with corpus luteum insufficiency, pregnancy rates would have been 83%, 54%, and 63%, and kidding rates 67%, 54%, and 63%, respectively. The average number of kids born was 1.88, 1.71, and 1.83, respectively (P > 0.05). It may be concluded that fixed time insemination of cycling does treated with prostaglandin F_2α during the luteal phase, followed by ovulation induction with GnRH or hCG, would be an effective management tool if it were possible to control the high incidence of corpus luteum insufficiency. The attempt to achieve this by substituting GnRH with hCG, was not met with success. Until a solution for the problem has been found, it is advisable to inseminate prostaglandin-synchronized does 16–18 hours after the onset of detected estrus.